<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04949308</url>
  </required_header>
  <id_info>
    <org_study_id>JR_nNO_PCD_09_2020</org_study_id>
    <nct_id>NCT04949308</nct_id>
  </id_info>
  <brief_title>Nasal Nitric Oxide Across Mutations in Primary Ciliary Dyskinesia</brief_title>
  <acronym>nNO_PCD</acronym>
  <official_title>High or Low. Nasal Nitric Oxide Across Mutations in Primary Ciliary Dyskinesia. A Genotype/Phenotype Analysis of Nasal NO in Patients With PCD Within the European Reference Network (ERN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NOVA Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Geneva, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leicester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bambino Gesù Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nicosia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Niños R. Gutierrez de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hacettepe University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marmara University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Motol</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Children's Hospital, Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leeds Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schneider Children's Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Belgrade</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Martin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abderrahmane Mami Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder characterized by dysfunction of&#xD;
      motile cilia associated with recurrent infections of the airways, laterality defects (Situs&#xD;
      inversus totalis in about 50% of cases) and fertility problems. At present, mutations in &gt; 45&#xD;
      genes associated with PCD and mucociliary clearance disorders have been identified,&#xD;
      representing most likely two thirds of all human cases.&#xD;
&#xD;
      The aims of this study are:&#xD;
&#xD;
        1. Correlation between nasal NO levels and distinct PCD genotypes&#xD;
&#xD;
        2. Determination of further parameters potentially associated with nasal NO levels in&#xD;
           genotyped PCD individuals&#xD;
&#xD;
             1. course of clinical manifestations (e.g. neonatal distress, infections,&#xD;
                bronchiectasis)&#xD;
&#xD;
             2. diagnostic results (HVMA, TEM, IF)&#xD;
&#xD;
             3. lung function outcome (FVC, FEV1)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nasal Nitric Oxide (nNO) concentration is usually low or very low in patients with Primary&#xD;
      Ciliary Dyskinesia (PCD) for yet unknown reasons (1).&#xD;
&#xD;
      Measured nNO holds a strong ability to separate healthy subjects from patients with PCD in&#xD;
      both childhood and adulthood and across several different nNO sampling modalities (2) (3-5)&#xD;
      and nNO is widely used as an important supplementary diagnostic test for PCD work up in both&#xD;
      Europe (6) and North America (7). Low nNO in PCD was first reported 26 years ago (8). Nasal&#xD;
      NO has been associated with host paranasal sinus defense as sufficient nNO production in&#xD;
      non-PCD subjects is thought to play a role in maintaining paranasal sinus sterility (9).&#xD;
      Furhermore, ciliary beating seems to be upregulated by a NO dependent pathway in bovine&#xD;
      airway epithelium (10), influencing mucociliary clearance. However, human in vitro studies of&#xD;
      ciliated airway cells in air-liquid-interface (ALI) culture have been ambiguous as to whether&#xD;
      the biosynthesis of NO in PCD is impaired (11) (12) or not (13; 14) and the etiology of low&#xD;
      nNO in PCD and presumed link to ciliary beating remains unclear. So far, attempts to link PCD&#xD;
      phenotype and genotype has indicated that patients with PCD harboring CCDC39 and CCDC40&#xD;
      mutations may have a poorer lung function development (15).&#xD;
&#xD;
      In rare cases of PCD (&lt;5%) (16) nNO concentration is within normal range. More than 14&#xD;
      different PCD-causing genes (e.g RSPH1, GAS8, RPGR, CCNO, CCDC103, CFAP221, DNAH9, FOXJ1,&#xD;
      GAS2L2, LRRC56, NEK10, SPEF2, STK36, TTC12) has been associated with nNO values above the&#xD;
      agreed cut off for nNO-production rate of 77 nL/min in a few patients with PCD (16). However,&#xD;
      individuals with NEK10 or FOXJ1 mutations, for example, display a very severe respiratory&#xD;
      phenotype (17), but making a diagnosis is challenging because of normal nNO values as well as&#xD;
      apparently normal ciliary beating.&#xD;
&#xD;
      Since nNO also holds potential as an outcome parameter in future clinical trials of PCD,&#xD;
      better understanding of nNO in PCD is warranted.&#xD;
&#xD;
      Demand of large number of patients with PCD is crucial, keeping the rareness of nearnormal&#xD;
      and normal nNO levels in PCD in mind. Motivated by the analysis of lung function in a large&#xD;
      cohort of genotyped PCD-patients, this multicenter Involvement across international PCD&#xD;
      centers is an obvious opportunity for gaining such further knowledge with the focus on nasal&#xD;
      NO.&#xD;
&#xD;
      The aims of this study are:&#xD;
&#xD;
        1. Correlation between nasal NO levels and distinct PCD genotypes&#xD;
&#xD;
        2. Determination of further parameters potentially associated with nasal NO levels in&#xD;
           genotyped PCD individuals&#xD;
&#xD;
             1. course of clinical manifestations (e.g. neonatal distress, infections,&#xD;
                bronchiectasis)&#xD;
&#xD;
             2. diagnostic results (HVMA, TEM, IF)&#xD;
&#xD;
             3. lung function outcome (FVC, FEV1)&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        1. Patients with a genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene,&#xD;
           known to cause PCD) with typical clinical symptoms of PCD&#xD;
&#xD;
        2. PCD individuals of all age groups with at least one nNO measurement performed according&#xD;
           to diagnostic guidelines. Serial nNO measurements should be included if available (e.g.&#xD;
           yearly), at least for infants and young children&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genotype-nasal Nitric Oxide Corelation</measure>
    <time_frame>up to 20 years retrospective</time_frame>
    <description>nNO in correlation to the genetic make-up</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Ciliary Motility Disorders</condition>
  <condition>Primary Ciliary Dyskinesia</condition>
  <arm_group>
    <arm_group_label>Genetic diagnosis</arm_group_label>
    <description>Genetic: Genetic diagnosis No Intervention foreseen, but genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD and at least one other method confirming PCD-diagnosis is needed</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene,&#xD;
        known to cause PCD) with typical clinical symptoms of PCD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a genetically confirmed diagnosis of PCD (bi-allelic mutations in a&#xD;
             gene, known to cause PCD) with typical clinical symptoms of PCD&#xD;
&#xD;
          2. PCD individuals of all age groups with at least one nNO measurement performed&#xD;
             according to diagnostic guidelines. Serial nNO measurements should be included if&#xD;
             available (e.g. yearly), at least for infants and young children&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heymut Omran, Prof,Dr,MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Muenster</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanna Raidt, MD</last_name>
    <phone>+49 251 83 40003</phone>
    <email>Johanna.Raidt@ukmuenster.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone Helms</last_name>
    <phone>+ 49 251 83 48358</phone>
    <email>Simone.Helms@ukmuenster.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Münster</name>
      <address>
        <city>Münster</city>
        <state>NRW</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heymut Omran, Prof, Dr, MD</last_name>
      <phone>+4925183</phone>
      <phone_ext>41097</phone_ext>
      <email>PCDregistry.eu@ukmuenster.de</email>
    </contact>
    <contact_backup>
      <last_name>Simone Helms</last_name>
      <phone>+4925183</phone>
      <phone_ext>48358</phone_ext>
      <email>Simone.Helms@ukmuenster.de</email>
    </contact_backup>
    <investigator>
      <last_name>Heymut Omran, Prof, Dr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johanna Raidt, MD, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciliary Motility Disorders</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

